AIM ImmunoTech Inc represents values of innovation, dedication, and patient-centricity. The company's corporate philosophy is centered around developing novel, cutting-edge immunotherapies that address unmet medical needs. AIM ImmunoTech Inc is committed to enhancing patient outcomes by harnessing the power of the immune system to target diseases such as cancer, viral infections, and immune disorders. Through rigorous research and clinical trials, the company continually strives to improve the quality of life for patients worldwide. AIM ImmunoTech Inc's mission is to provide effective and safe therapies that revolutionize the treatment landscape, offering hope and improved health outcomes for individuals facing these challenging conditions.

AIM ImmunoTech Inc is primarily present in the United States of America (USA).

AIM ImmunoTech Inc. has achieved several significant milestones in its journey. The company has made notable strides in the field of immune system-based technologies and therapies. They successfully developed and gained regulatory approval for various products, including Ampligen® and Alferon N Injection®, which have shown promising results in the treatment of different diseases. AIM ImmunoTech Inc. has also established partnerships and collaborations with renowned research organizations, facilitating advancements in the medical community. Additionally, the company has made noteworthy progress in clinical trials, expanding its understanding of the therapeutic potential of its products. These milestones highlight AIM ImmunoTech Inc.'s commitment to advancing innovative solutions in the biomedical field.

AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida. Founded in 1966, AIM ImmunoTech specializes in the development and commercialization of immunotherapy-based treatments for various medical conditions. The company focuses on harnessing the power of the immune system to fight diseases such as cancer, viral infections, and autoimmune disorders. AIM ImmunoTech is well-known for its drug Ampligen, which has shown promise in treating chronic fatigue syndrome and certain types of cancers. With a rich history spanning over 50 years, AIM ImmunoTech is dedicated to advancing innovative therapies to improve patients' lives.

Some of the main competitors of AIM ImmunoTech Inc in the market include companies like Bristol-Myers Squibb, Merck & Co., and Novartis. These pharmaceutical giants also focus on developing and commercializing innovative immunotherapies and pharmaceutical products. AIM ImmunoTech Inc faces competition in the areas of drug research and development, clinical trials, market penetration, and product adoption. Despite this competitive landscape, AIM ImmunoTech Inc strives to differentiate itself through its unique approach to immunotherapy and the development of potential treatments for diseases such as cancer and viral infections.

AIM ImmunoTech Inc is primarily active in the biotechnology and pharmaceutical industries.

AIM ImmunoTech Inc is a biopharmaceutical company focused on developing and commercializing immunotherapy products for the treatment of multiple diseases. Their business model revolves around the development of novel therapeutics and immune system stimulants to address significant unmet medical needs. AIM ImmunoTech Inc aims to leverage their expertise in immune system modulation to develop innovative treatments that can potentially improve patient outcomes. Through their research and development efforts, they strive to introduce effective and safe immunotherapies that may offer new hope for patients suffering from various diseases.

AIM ImmunoTech KGV ir -0,75.

AIM ImmunoTech KUV ir 133,35.

AlleAktien kvalitātes vērtējums AIM ImmunoTech ir 5/10.

gaidāmā AIM ImmunoTech apgrozījums ir 134 663,30 USD.

gaidāmā AIM ImmunoTech peļņa ir -24,05 milj. USD.

AIM ImmunoTech Inc is a biotechnology company that focuses on developing immunotherapies for the treatment of serious diseases such as cancer and infectious diseases. The company is a pioneer in the field of immune stimulants, which stimulate the body's immune system to intervene in cancer cells and infected cells. The company operates in two main business areas - oncology and infectious diseases. In the oncology business, AIM ImmunoTech focuses on developing immune stimulants as adjuncts to chemotherapy and radiation in the fight against cancer. AIM ImmunoTech's flagship immunotherapy is Ampligen®, an immune stimulant that has shown potential as a cancer immunotherapy and is frequently used in clinical studies in cancer patients. The company also intends to further develop its immunotherapy candidates to improve their effectiveness. In the field of infectious diseases, AIM ImmunoTech Inc focuses on antiviral and antibacterial therapeutic solutions. Given the current COVID-19 pandemic, the company has received particular attention as Ampligen® has shown promising results in improving the immune systems of COVID-19 patients. The company is also working on the development of antiviral and antimicrobial agents to combat infections such as herpes simplex viruses, Ebola virus, and Rift Valley fever. In addition to developing immune stimulants as immunotherapy candidates, AIM ImmunoTech also operates business units such as the sales and marketing of ImmuBoost®, a dietary supplement containing natural immune boosters. Furthermore, the company has planned the development of products in close cooperation with life science companies such as Shandong Buchang Pharmaceutica and Yangtze River Pharmaceutical. AIM ImmunoTech Inc also collaborates closely with academic institutions and individuals to expand the scientific understanding of different diseases and their treatment. The company is proud to be a central component in the fight against cancer and infectious diseases and hopes to soon present an important addition to the medical portfolio. Overall, AIM ImmunoTech Inc takes a multidimensional approach to immunotherapy product development and marketing and operates a wide range of business areas. The company is committed to continuously strengthening its business model and expanding its position as a tireless innovator and leader in the biotechnology industry.

AIM ImmunoTech izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt AIM ImmunoTech vai uzņēmums nedod dividendes.

AIM ImmunoTech ISIN ir US00901B1052.

AIM ImmunoTech WKN ir A2PREX.

AIM ImmunoTech simbols ir AIM.

Pēdējo 12 mēnešu laikā AIM ImmunoTech maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos AIM ImmunoTech plāno maksāt dividendes 0 USD apmērā.

AIM ImmunoTech pašreizējā dividendu rentabilitāte ir .

AIM ImmunoTech maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

AIM ImmunoTech pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

AIM ImmunoTech tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu AIM ImmunoTech apmērā 0 USD, kas tika izmaksāta 26.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.08.2024..

Pēdējās dividendes izmaksa notika 26.08.2024..

Gadā 2023, AIM ImmunoTech izmaksāja 0 USD dividendes.

AIM ImmunoTech dividendes tiek izmaksātas USD.